Chinese Public Payer Data Show More New Drugs Get Faster Coverage
But Pricing Trade-Off
Executive Summary
China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.